drugset / Trial / NCT05415657

Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery

NCT05415657

Completed 76 enrolled Shenzhen People's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Degenerative lumbar spinal diseases have become a common health problem and the most frequent indication for spinal surgery in elderly individuals. It mainly contain lumbar spinal stenosis and spondylolisthesis, occurs in most people over 60 years of age, and patients primarily diagnosed with lumbar degenerative disease are more likely to have osteoporosis. Our study was to explore denosumab effect on bone quality and functional status in osteopenia patients with lumbar degenerative diseases after lumbar fusion surgery.

Timeline

Start
2020-01-12
Primary completion
2023-01-05
Completion
2023-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications